Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug Pipeline

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Novo Nordisk (CPSE:NOVO B) has kicked off a Phase 1 trial of LX9851, an oral, non-incretin obesity drug licensed from Lexicon Pharmaceuticals, bringing fresh attention to the breadth of its weight loss pipeline.

See our latest analysis for Novo Nordisk.

Despite a steady stream of obesity drug developments and regulatory news, including the Wegovy HD approval and the LX9851 trial start, Novo Nordisk’s 30-day share price return of 21.11% and year to date share price return of 28.10% sit against a 1-year total shareholder return of 53.18% and a 3-year total shareholder return of 53.49%. This suggests momentum has faded recently, even after a 5-year total shareholder return of 18.28%.

If this kind of obesity and metabolic health story has your attention, it can be worth scanning for other healthcare names pushing into AI enhanced treatments using the Simply Wall St screener for 127 healthcare AI stocks

So with Novo Nordisk’s share price showing recent double digit declines over 30 days and year to date, yet trading at what appears to be a discount to analyst targets and some intrinsic estimates, are you looking at a fresh entry point or a market that is already pricing in the next leg of growth?

Most Popular Narrative: 72.1% Undervalued

Tokyo’s widely followed narrative pegs Novo Nordisk’s fair value at DKK851.04 per share, which sits well above the last close at DKK237.45 and sharply contrasts with the recent share price slide.

Novo Nordisk has built a formidable economic moat ("Burggraben") through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand. With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform. This windfall is now driving massive capital inflows, which Novo Nordisk is wisely reinvesting to secure its leadership for decades to come.

Read the complete narrative.

Curious how that fair value is built? The narrative leans on robust revenue expansion, firm margins and a future earnings multiple that reflects sustained strength in obesity and diabetes therapies.

Result: Fair Value of DKK851.04 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat story could be challenged if GLP 1 pricing or reimbursement shifts, or if newer obesity treatments weaken the current economic moat.

Story Continues

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

With sentiment split between opportunity and risk, it helps to move quickly and check the numbers yourself, starting with the 4 key rewards and 5 important warning signs.

Looking for more investment ideas?

If Novo Nordisk has sharpened your interest, do not stop here. Use the screener to quickly surface other opportunities that might fit your style and goals.

Spot potential bargains early by scanning companies that screen as high quality and undervalued through the 235 high quality undervalued stocks. Prioritize resilience by searching for businesses highlighted in the 272 resilient stocks with low risk scores that show lower overall risk profiles. Hunt for lesser known opportunities by checking the screener containing 588 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO-B.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments